However, Phase III clinical trials revealed that while “Tofersen” reduces SOD1 protein and neurofilament light chain (NfL) levels in cerebrospinal fluid (CSF), it failed to significantly improve ALS Functional Rating Scale-Revised (ALSFRS-R) scores (Hamad et al., 2025). This evidence concerns the gene NEFL and amyotrophic lateral sclerosis.